Boehringer Ingelheim Pharmaceuticals, broke ground on a new $42.5-million safety assessment building to be built over the next two years on its 294-acre campus in Ridgefield and Danbury, according to the Ridgefield Press.
The building, when completed in 2013, will provide more than 63,000 square feet of space for non-clinical safety studies in development as well as studies for research.
“The fact that Boehringer Ingelheim continues to invest in its campus and create jobs is great news for Connecticut,” said Connecticut Gov. Malloy. “This new facility expands the company’s research and development capacities, and reaffirms its reputation as an innovative and forward-looking company. Boehringer Ingelheim is a valued member of the Connecticut business community and a key partner in our collective efforts to strengthen the state’s bioscience industry.”
This new facility is a world class design combining state-of-the-art technology, compliance with current good manufacturing practice and process flexibility to handle production of the many different types of APIs discovered in research, Boehringer said.